medRxiv preprint doi: https://doi.org/10.1101/2022.02.07.22269889; this version posted February 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Validating saliva as a biological sample for cost-effective, rapid and routine 1 2 screening for SARS-CoV-2 3 B.R. Ansil^a*, Carolin Elizabeth George^b, Sindhulina Chandrasingh^c, Ashwin Viswanathan^d, 4 Mukund Thattai^a, Padinjat Raghu^a, Santhosha Devadiga^e, Arun Geetha Harikumar^e, Pulleri 5 6 Kandi Harsha^e, Indu Nair^f, Uma Ramakrishnan^a*, Satvajit Mayor^a 7 ^a National Centre for Biological Sciences, Tata Institute of Fundamental Research, 8 9 Bangalore, Karnataka, India 560065 10 11 ^b Community Health and Research Division, Bangalore Baptist Hospital, Bangalore, 12 Karnataka, India 560024 13 14 ^c Department of Microbiology, Bangalore Baptist Hospital, Bangalore, Karnataka, India 15 560024 16 ^d Nature Conservation Foundation, Mysore, Karnataka, India 570017 17 18 19 ^e COVID-19 Testing Laboratory, Institute for Stem Cell Science and Regenerative Medicine, 20 Bangalore Life Science Cluster, Bangalore, Karnataka, India 560065 21 22 ^f Department of Medicine and Infectious diseases, Bangalore Baptist Hospital, Bangalore, 23 Karnataka, India 560024 24 25 * Gernesponding, author: ansilbra nobs result (ABR); ura makring nobs rest in our Bunical practice.

26 Abstract

27 *Purpose*: Compared to nasopharyngeal/oropharyngeal swabs, non-invasive saliva samples

28 have enormous potential for scalability and routine population screening of SARS-CoV-2. In

- 29 this study, we are investigating the efficacy of saliva samples relative to
- 30 nasopharyngeal/oropharyngeal swabs for use as a direct source for the RT-PCR based SARS-
- 31 CoV-2 detection.
- 32 *Methods*: Paired nasopharyngeal/oropharyngeal swabs and saliva samples were collected

33 from suspected positive SARS-CoV-2 patients and tested using RT-PCR. Generalised linear

34 models were used to investigate factors that explain result agreement. Further, we used

35 simulations to evaluate the effectiveness of saliva-based screening in restricting the spread of

36 infection in a large campus such as an educational institution.

37 *Results*: We observed 75.4% overall result agreement. Prospective positive samples stored for

38 three or more days showed a drastic reduction in the probability of result agreement. We

39 observed 83% result agreement and 74.5% test sensitivity in samples processed and tested

40 within two days of collection. Our simulations suggest that a test with 75% sensitivity, but

41 high daily capacity can be very effective in limiting the size of infection clusters in a

42 workspace. Guided by these results, we successfully implemented a saliva-based screening in

43 the Bangalore Life Sciences Cluster (BLiSC) campus.

44 Conclusion: These results suggest that saliva may be a viable sample source for SARS-CoV-

45 2 surveillance if samples are processed immediately. We strongly recommend the

46 implementation of saliva-based screening strategies for large workplaces and in schools, as

47 well as for population-level screening and routine surveillance as we learn to live with the

48 SARS-CoV-2 virus.

49

50 Keywords: SalivaDirect, SARS-CoV-2, Non-invasive, Cost-effective, Surveillance

51 Introduction

52 The COVID-19 pandemic spread rapidly in India, infecting more than 30 million people in 53 two years [1]. Given this magnitude and speed, COVID-19 presents various diagnostic 54 challenges, in the context of massive population density and limited diagnostic and health 55 infrastructure capabilities. Viral diagnosis has progressed tremendously, and of the various modalities for SARS-CoV-2 diagnosis, the most reliable test is the reverse transcription-56 57 polymerase chain reaction (RT-PCR) on Nasopharyngeal/Oropharyngeal swabs collected in 58 Viral Transport Medium (N/OPS-VTM). This demands skilled technical staff, involves 59 procedural complexities such as viral inactivation and RNA extraction. Besides, the sample 60 collection protocol causes significant discomfort to the patient [2] and demands strict 61 protocols for prevention of infection to healthcare workers. These procedural complexities of 62 the test are associated with increased cost and turnaround time. 63 The SalivaDirect is an alternative RNA extraction free, cost-effective RT-PCR-based 64 65 protocol with a short turnaround time and less dependence on the supply chain [3]. Using 66 saliva as a source sample has several advantages: 1) samples can be collected by patients 67 without the help of trained personnel, 2) stringent personal protective equipment (PPE) are not required, 3) non-invasive routine testing is possible 4) dispensing with swabs or VTM 68 69 adds flexibility, and 5) no requirement for RNA extraction reduces the cost and hence widens its applicability. Evidence related to using saliva for SARS-CoV-2 testing is evolving, and 70 71 recent studies have reported promising results [4, 5]. Unfortunately, saliva-based tests in 72 India are explored by very few studies [5, 6].

73

In this study, we assessed the performance of saliva relative to N/OPS-VTM samples for use
as a direct source (without RNA extraction) for the RT-PCR based SARS-CoV-2 detection.

76 We also investigated correlates for discordance between N/OPS-VTM and saliva sample 77 pairs. Further, we used simulations that incorporate concordance to evaluate the effectiveness 78 of SalivaDirect in restricting the infection spread in a large campus such as an educational 79 institution. Finally, we present a case study on the implementation of such a strategy in an 80 educational institution. Through this study, we provide evidence for a low cost, easy, fast, and accurate test that has a considerable advantage in a country like India, especially in 81 82 learning to 'live with the virus'. 83 84 **Materials and Methods** 85 *Ethical statement* 86 The study was approved by the Institutional Review Board of Bangalore Baptist Hospital

87 (BBB/IRB/2020/010); Institutional Human Ethics Committee and Institutional Biosafety

88 Committee, National Centre for Biological Sciences (NCBS/IEC-22/01, NCBS/IEC-26/,

89 NCBS:34IBSC/UR1).

90

91 Sample collection, processing and testing for SARS-CoV-2

92 Samples were obtained from patients of Bangalore Baptist Hospital between December 2020 93 and May 2021. From each individual, a N/OPS-VTM and saliva (5 ml) were collected. Each 94 paired sample was given a unique biorepository number and transported to the COVID-19 95 testing laboratory at Institute for Stem Cell Science and Regenerative Medicine (inStem). 96 Upon arrival, samples were stored in a 4°C refrigerator in the biosafety laboratory. Storage 97 time before processing the samples varied from 0 to 15 days with a mean of 4 days. In case of 98 storage beyond two days, the samples were moved to a -20°C freezer. 99 N/OPS-VTM samples were processed following the Indian Council of Medical Research 100 (ICMR) approved protocol. RNA was extracted using a magnetic bead-based automated Viral

101 RNA Extraction protocol (Beckman Coulter Life Sciences). Saliva were processed following 102 SalivaDirect protocol [3] and tested for RdRP, E and N genes of SARS-CoV-2 and human 103 RNase P gene using NeoDx-CoviDx[™] mPlex-4R SARS-CoV-2 RT-PCR Detection kits. Test 104 results were evaluated based on manufacturer's guidelines. Detailed sample collection and 105 testing strategies are provided in the Supplementary material. 106 107 Analysis 108 We determined (a) the number of individuals positive for SARS-CoV-2 in both N/OPS-VTM 109 and saliva, (b) those positive only in N/OPS-VTM, (c) those positive only in saliva, and (d) 110 those negative in both N/OPS-VTM and saliva. From this data, we computed the test 111 sensitivity on each sample type. Since nasopharyngeal swab sampling has been shown to 112 produce false negatives by RT-PCR [7], sensitivities for the saliva and the N/OPS-VTM are 113 defined here respectively as (a+c)/(a+b+c) and (a+b)/(a+b+c), considering any individual 114 with a positive result on one or the other sample as true positive [4]. 115 116 We compared positive outcomes from the saliva results with true positives and used a 117 Generalized Linear Model (GLM) to understand the factors that explain result agreement (or 118 disagreement). We modelled result agreement/disagreement (success/failure) as a function of 119 the sex of the patient, age, severity of the symptoms (asymptomatic and symptomatic), and 120 storage duration (number of days between collection and testing; grouped into two bins: 0-2 121 days and 3-15 days), assuming a binomial error distribution. This analysis did not include 122 individuals showed inconclusive results. We also assessed the Ct-value distribution of all test 123 genes for concordant samples and compared using Wilcoxon test [8]. 124 125 Modelling infection spread on a network

126 We explored the effectiveness of campus-wide saliva-based screening using a Monte Carlo 127 simulation of infection transmission in a network of 1600 individuals. In the simulation, a 128 subset of individuals are tested each day, and test results are reported after some delay. 129 Individuals who test positive are isolated, and their contacts are subsequently tested and 130 isolated if positive. We start with a single positive case and run the simulation until there are 131 no infected individuals remaining. The model is stochastic, so each run of the simulation 132 produces a different result. The total number of infections at the end of the simulation defines 133 the size of the cluster. An important goal of mitigation is to limit the size of a cluster seeded 134 by a single infection. The model used for simulation is described in the Supplementary 135 material.

136

137 Results

138 SARS-CoV-2 detection in paired N/OPS-VTM and saliva samples

139 We observed 75.4% overall result agreement between N/OPS-VTM and saliva sample pairs;

140 30.3% positive agreement and 45.1% negative agreement (Table 1). The inconclusive results

141 were 1.1% and 5.7% for N/OPS-VTM and saliva, respectively. Interestingly, 3.4% of saliva

142 samples were positive when the corresponding N/OPS-VTM were negative. The sensitivity

143 of saliva and N/OPS-VTM were 70.2% and 92.9%, respectively.

144 In the GLM with four variables, duration of storage was independently associated with result

145 agreement (Supplementary Table 1). Among N/OPS-VTM positive or saliva positive

146 patients, we observed a clear drop in result agreement (Fig 1) from 80.8% (SE 70.7-88) to

147 55.5% (SE 45.7-64.9) when samples were stored for more than two days (p=0.025).

148 Concordance (83%) and the sensitivity (74.5%) of the saliva test improved when we

149 considered only the samples tested within two days of collection (Table 2). This also resulted

150 in a significant improvement (decrease) in inconclusive test results (1.8% in saliva and 0.9%

151 in N/OPS-VTM). We also found that viral loads were statistically indistinguishable in 152 positive sample pairs for all three viral genes (Wilcoxon p > 0.05, Fig 2) among positive 153 concordant samples.

154

155 Simulations reveal that saliva-based screening can limit infection spread

156 We track the probability that a single starting infection leads to a large cluster (of size 25 or 157 more) as the testing parameters are varied (Fig 3). This model is not meant to replicate the 158 transmission dynamics of an actual workforce; rather, it is a proof of principle to identify key 159 factors that influence the success of screening. We focus on three key factors of the testing 160 protocol: (a) sensitivity, (b) daily testing capacity, (c) delay in reporting results. In our 161 simulations, in the absence of testing and isolation, the probability of a large cluster is 20% 162 under the assumed parameter values. However, by using a test with 75% sensitivity, at 200 163 tests per day with a one-day delay for results, we decrease the probability of a large cluster 164 ten-fold, to about 2%. Moreover, this protocol works better than a test with 100% sensitivity, 165 but with half the capacity or twice the delay.

166

167 Implementation of a saliva screening program

168 In the light of these results, we implemented saliva-based screening in Bangalore Life 169 Science Cluster (BLiSC) campus of ca. 1400 adults. Participants donated a saliva sample 170 once every seven days, and information was collected using a mobile phone application. 171 Individuals were instructed on the sample collection protocol using a video played at the 172 collection centre with no verbal instruction. Samples were tested on the same day, the 173 maximum delay between sample collection and testing being ca. 8 hrs. Over six months, we 174 tested ca. 20000 saliva f samples for SARS-CoV-2 using the protocols described here. An 175 average of 160 samples were tested each day, with a maximum of 300 samples on a single

176 day. Samples were collected between 10 am and 2 pm Monday to Friday, processed in about 177 6 hrs, with final results delivered soon after (the same evening) via mobile phones. Over 178 these six months, we noted only ca. 10 instances where amplification of the internal control 179 (RP) did not occur, presumably due to inhibitory factors in the collected saliva. Over that 180 same period, nine saliva samples tested positive. Of these, eight individuals were completely 181 asymptomatic, and one had very mild generic symptoms suggestive of an upper respiratory 182 tract infection. Among these nine individuals, three tested positive on NP swabs collected on 183 the same day, one tested negative, and the remaining 5 declined further testing and preferred 184 to isolate as per public health guidelines.

185

186 **Discussion**

187 Saliva is emerging as an effective alternative sample type for SARS-CoV-2 testing, with very 188 high sensitivity and specificity [3, 9]. However, N/OPS-VTM remain the more effective 189 sample type for routine diagnosis. Within this context, we examine the efficacy of the saliva 190 for direct RT-PCR and their potential for large-scale testing. Our results suggest that saliva is 191 an excellent alternative to conventional N/OPS-VTM with a reasonable concordance. The 192 overall result agreement between N/OPS-VTM and saliva was 75.4%, slightly lower than 193 reported in recent studies [10, 11]. This reduction in result agreement could be attributed to 194 the longer storage duration of samples, timing of sampling and severity of the disease [12]. 195 Since saliva samples were collected without any stabilization media, RNA stability might 196 have been compromised during the storage and freeze-thaw, resulting in lower positivity [13, 197 14]. When recalculated for samples with less than two days of storage, concordance (83%) 198 and sensitivity (74.5%) were closer to those reported in several recent studies [4]. 199

200 The sensitivity of saliva was lower than that of N/OPS-VTM. This could be because most 201 samples were follow-up samples of admitted positive patients collected after a week of 202 hospitalisation. Many would have been symptomatic for more than two weeks; however, this 203 information was unavailable. Recent studies have found a higher percentage of viral 204 positivity in saliva when collected within ten days of COVID-19 diagnosis [15, 16]. Delayed 205 sample collection could have been a reason for the low saliva sensitivity in our study. 206 Another important finding of this study is that the Ct value comparison of three viral genes 207 for samples with positive result agreement showed no significant variation. This suggests that 208 these samples would have been taken in the initial phase of the infection. It also indicates that 209 both positive N/OPS-VTM and saliva samples had a similar viral load, suggesting saliva is a 210 valuable alternative sample type for SARS-CoV-2 detection [17].

211

212 Testing of asymptomatic individuals in a workforce is a proactive approach that can help 213 identify and isolate sources of SARS-CoV-2 infection. In choosing the testing protocol, one 214 confronts a trade-off between test sensitivity on the one hand, and testing capacity and testing 215 delay on the other. For example, Rapid Antigen Tests produce immediate results with low 216 sensitivity, while the gold-standard N/OPS RT-PCR test achieves high sensitivity but with 217 limited capacity and delayed results. Furthermore, even a 100% sensitive test cannot prevent 218 spread, since only a fraction of individuals are sampled each day, and individuals in early 219 stages of infection may not test positive. We explored these trade-offs using a simulation of 220 infection transmission. We found that increased testing capacity and decreased delay more 221 than offset decreased test sensitivity, in preventing the emergence of large infection clusters. 222 In particular, higher testing capacity enabled a more rapid cycle for testing an entire 223 workforce, increasing the chance that an infection missed in one cycle was picked up in the 224 next.

225

226 The saliva-based protocol described here meets the criteria highlighted above, for effective 227 workplace screening. It is non-invasive, simple and self-collected without any PPE and can 228 be used directly for RT-PCR [18]. The SalivaDirect protocol does not require RNA 229 extraction, a significant bottleneck in the testing workflow [3]. These unique features of 230 saliva screening significantly reduce testing costs and complexity when compared to N/OPS-231 VTM testing although we have not performed a formal cost analysis. Adopting saliva-based 232 screening could yield higher testing capacity and shorter delays in result reporting. In case of 233 resource constraints, saliva pooling can also be employed to further reduce overall turnaround 234 time and test burden [19, 20]. Given these benefits, as well as the observed concordance 235 between N/OPS-VTM and saliva, we piloted saliva-based screening to detect COVID-19 236 infections in the BLiSC academic campus. We found that this screening and surveillance 237 effort was successful, enabling the campus to remain functional during the ongoing COVID-238 19 pandemic in India. Regular screening, which depends heavily on participant compliance, 239 allows the resumption of normal workplace activity with enhanced safety with respect to 240 COVID-19 infection. The approach described here can be scaled up for routine surveillance 241 efforts, and implemented in schools, offices, academic institutions, and residential 242 apartments.

243

244 Conclusion

While there is substantial evidence for saliva as a source sample for SARS-CoV-2 detection globally, we present here a comprehensive study where we validate saliva as a screening tool for SARS-CoV-2 in India. Simulations aimed at detecting infection clusters guided the setup of a regular saliva-based screening on an academic campus, given estimates of concordance between saliva and nasopharyngeal/oropharyngeal swabs. Finally, we highlight the successful

implementation of such a strategy on an academic campus. We hope this study can serve as
an example and provide guidelines for the setup of a rapid and efficient approach to safe
functioning of large establishments, including schools and industries, in the coming years as
the world continues to live through a pandemic.

254

255 Acknowledgements

256 This work was primarily supported by NCBS/TIFR core fund, and we acknowledge the

support of the Department of Atomic Energy (DAE), Government of India, under Project

258 Identification No. RTI 4006; and philanthropic support from the Azim Premji Foundation.

259 We acknowledge the CCAMP-InDx program for facilitating the saliva collection receptacle

and transport medium from Kriyamed (<u>https://www.kriyamed.com/</u>) for campus screening.

261 We are grateful to COVID-19 testing laboratory staff for helping with sample processing and

262 RT-PCR testing; Mr. Prem Chandra Gautam, technical and research services teams at NCBS

263 for their assistance in implementing campus saliva testing. We thank Prof. Apurva Sarin and

264 Prof. Colin Jamora for facilitating the project. ABR is supported by the SPM research

265 fellowship by CSIR-HRDG. UR is a Senior fellow DBT-Wellcome Trust India Alliance

266 (IA/S/16/2/502714). SM is a JC Bose Fellow of the Department of Science and Technology,

267 Government of India, and a Margadarshi Fellow of the DBT-Wellcome Trust India Alliance

268 (IA/M/15/1/502018).

269

270 **CRediT** author statement

271 B.R. Ansil: Conceptualization, Data curation, Analysis, Writing - Original Draft, Writing -

272 Review and Editing. Carolin Elizabeth George: Conceptualization, Data curation, Analysis,

273 Writing - Original Draft, Writing - Review and Editing. Sindhulina Chandrasingh:

274 Conceptualization, Data curation, Writing - Original Draft, Writing - Review and Editing.

- 275 Ashwin Viswanathan: Conceptualization, Analysis, Writing Original Draft, Writing -
- 276 Review and Editing. Mukund Thattai: Conceptualization, Methodology, Analysis, Writing -
- 277 Original Draft, Writing Review and Editing. Padinjat Raghu: Conceptualization,
- 278 Methodology, Writing Original Draft, Writing Review and Editing. Santhosha Devadiga:
- 279 Investigation, Data curation. Arun Geetha Harikumar: Investigation, Data curation,
- 280 Writing Review and Editing. Pulleri Kandi Harsha: Investigation, Data curation. Indu
- 281 Nair: Conceptualization, Data curation. Uma Ramakrishnan: Conceptualization, Writing -
- 282 Original Draft, Writing Review and Editing, Supervision. Satyajit Mayor:
- 283 Conceptualization, Writing Review and Editing and Supervision.
- 284

285 Conflict of Interest

286 The authors declare that they have no conflict of interest.

287 **References**

- https://www.mohfw.gov.in (2021) Ministry of Health and Family Welfare, Government
 of India. Accessed 10 Dec 2021
- 290 2. Wang H, Liu Q, Hu J, et al (2020) Nasopharyngeal Swabs Are More Sensitive Than
- 291 Oropharyngeal Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2
- 292 Load. Front Med 7:334. https://doi.org/10.3389/fmed.2020.00334
- 293 3. Vogels CBF, Watkins AE, Harden CA, et al (2021) SalivaDirect: A simplified and
- flexible platform to enhance SARS-CoV-2 testing capacity. Med 2:263-280.e6.
- 295 https://doi.org/10.1016/j.medj.2020.12.010
- 4. Ibrahimi N, Delaunay-Moisan A, Hill C, et al (2021) Screening for SARS-CoV-2 by
- 297 RT-PCR: Saliva or nasopharyngeal swab? Rapid review and meta-analysis. PLOS ONE

298 16:e0253007. https://doi.org/10.1371/journal.pone.0253007

- 299 5. Azmi I, Faizan MI, Kumar R, et al (2021) A Saliva-Based RNA Extraction-Free
- 300 Workflow Integrated With Cas13a for SARS-CoV-2 Detection. Front Cell Infect
- 301 Microbiol 11:632646. https://doi.org/10.3389/fcimb.2021.632646
- 302 6. Bhattacharya D, Parai D, Rout UK, et al (2021) Saliva for diagnosis of SARS-CoV-2:
- 303 First report from India. J Med Virol 93:2529–2533. https://doi.org/10.1002/jmv.26719
- 304 7. Woloshin S, Patel N, Kesselheim AS (2020) False Negative Tests for SARS-CoV-2
- 305 Infection Challenges and Implications. N Engl J Med 383:e38.
- 306 https://doi.org/10.1056/NEJMp2015897
- 307 8. Wilcoxon F (1945) Individual Comparisons by Ranking Methods. Biom Bull 1:80.
- 308 https://doi.org/10.2307/3001968

- 309 9. Butler-Laporte G, Lawandi A, Schiller I, et al (2021) Comparison of Saliva and
- 310 Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-
- 311 CoV-2: A Systematic Review and Meta-analysis. JAMA Intern Med 181:353.
- 312 https://doi.org/10.1001/jamainternmed.2020.8876
- 313 10. Landry ML, Criscuolo J, Peaper DR (2020) Challenges in use of saliva for detection of
- 314 SARS CoV-2 RNA in symptomatic outpatients. J Clin Virol 130:104567.
- 315 https://doi.org/10.1016/j.jcv.2020.104567
- 316 11. Vaz SN, Santana DS de, Netto EM, et al (2020) Saliva is a reliable, non-invasive
- 317 specimen for SARS-CoV-2 detection. Braz J Infect Dis 24:422–427.
- 318 https://doi.org/10.1016/j.bjid.2020.08.001
- 319 12. Iwasaki S, Fujisawa S, Nakakubo S, et al (2020) Comparison of SARS-CoV-2 detection
- 320 in nasopharyngeal swab and saliva. J Infect 81:e145–e147.
- 321 https://doi.org/10.1016/j.jinf.2020.05.071
- 322 13. Matic N, Stefanovic A, Leung V, et al (2021) Practical challenges to the clinical
- 323 implementation of saliva for SARS-CoV-2 detection. Eur J Clin Microbiol Infect Dis
- 324 40:447–450. https://doi.org/10.1007/s10096-020-04090-5
- 325 14. Pasomsub E, Watcharananan SP, Watthanachockchai T, et al (2021) Saliva sample
- 326 pooling for the detection of SARS-CoV-2. J Med Virol 93:1506–1511.
- 327 https://doi.org/10.1002/jmv.26460
- 328 15. Wyllie AL, Fournier J, Casanovas-Massana A, et al (2020) Saliva or Nasopharyngeal
- 329 Swab Specimens for Detection of SARS-CoV-2. N Engl J Med 383:1283–1286.
- 330 https://doi.org/10.1056/NEJMc2016359

- 331 16. Uwamino Y, Nagata M, Aoki W, et al (2021) Accuracy and stability of saliva as a
- 332 sample for reverse transcription PCR detection of SARS-CoV-2. J Clin Pathol 74:67–
- 333 68. https://doi.org/10.1136/jclinpath-2020-206972
- 17. Yokota I, Hattori T, Shane PY, et al (2021) Equivalent SARS-CoV-2 viral loads by PCR
- between nasopharyngeal swab and saliva in symptomatic patients. Sci Rep 11:4500.
- 336 https://doi.org/10.1038/s41598-021-84059-2
- 18. Medeiros da Silva RC, Nogueira Marinho LC, de Araújo Silva DN, et al (2020) Saliva
- as a possible tool for the SARS-CoV-2 detection: A review. Travel Med Infect Dis
- 339 38:101920. https://doi.org/10.1016/j.tmaid.2020.101920
- 340 19. Perchetti GA, Sullivan K-W, Pepper G, et al (2020) Pooling of SARS-CoV-2 samples to
- 341 increase molecular testing throughput. J Clin Virol 131:104570.
- 342 https://doi.org/10.1016/j.jcv.2020.104570
- 343 20. Watkins AE, Fenichel EP, Weinberger DM, et al (2020) Pooling saliva to increase
- 344 SARS-CoV-2 testing capacity. Infectious Diseases (except HIV/AIDS)

346 **Tables and Figures**

347

- 348 Table 1: A matrix showing the alignment of results from the two methods N/OPS-VTM
- and Saliva for all samples (N = 175). The asterisk indicate result agreements.


N/OPS-VTM (N=175)									
Saliva (N=175)		Positive	Negative	Inconclusive	Total				
	Positive	30.3% (53)*	3.4% (6)	0.6% (1)	34.3% (60)				
	Negative	14.3% (25)	45.1% (79)*	0.6% (1)	60.0% (105)				
	Inconclusive	5.7% (10)	0.0% (0)	0.0% (0)	5.7% (10)				
	Total	50.3% (88)	48.6% (85)	1.1% (2)	175				

350

351

- **Table 2:** A matrix showing the alignment of results from the two methods N/OPS-VTM
- and Saliva for samples tested within two days of collection (N = 112). The asterisk indicate
- 354 result agreements.


N/OPS-VTM (N=112)								
Saliva (N=112)		Positive	Negative	Inconclusive	Total			
	Positive	27.7% (31)*	3.6% (4)	0.9% (1)	32.1% (36)			
	Negative	10.7% (12)	55.4% (62)*	0.9% (1)	67.0% (75)			
	Inconclusive	0.9% (1)	0.0% (0)	0.0% (0)	0.9% (1)			
	Total	39.3% (44)	59.0% (66)	1.8% (2)	112			



356

357 Fig 1: Probability of result agreement in positive samples (0-2 days: N = 49; 3-15 days: N =46). Samples stored for more than two days showed high result disagreement between paired 358 359 samples. Error bars are standard errors and the asterisk denotes a significant difference.


360





362 Fig 2: Boxplot showing Ct value distribution for three SARS-CoV-2 genes and human RNAse P gene. There is no significant difference in mean Ct values for viral genes between 363 364 N/OPS-VTM and saliva samples.





366

Fig 3: Results of a Monte Carlo simulation of infection transmission on a network of 1600 367 368 individuals. We track the probability that a single starting infection seeds a cluster of 25 or 369 more infections. We compare a baseline protocol that has a capacity of 200 tests per day and a delay in reporting of one day (green), with variations having higher or lower capacities or 370 371 delays (see legend). Error bars represent SEM values over 5000 replicate simulations. 372